A Phase 3, Multicenter, 20-Week, Double-Blind and 32-Week Open-Label Study to Evaluate the Efficacy and Safety of X0002 Spray in Relief of the Signs and Symptoms of Subjects With Osteoarthritis of the Lumbar Spine
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Ibuprofen (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Techfields Pharma
- 27 Dec 2017 Planned initiation date changed from 10 Dec 2017 to 10 Apr 2018.
- 10 Oct 2017 Planned initiation date changed from 10 Jul 2017 to 10 Dec 2017.
- 17 Apr 2017 New trial record